Skip to main content
. 2021 Feb 12;5:10. doi: 10.1038/s41698-021-00147-6

Table 4.

Evaluation of response to c4G12 treatment.

Best overall response—no. (%)
 CR 1 (7.7)
 PR 0 (0)
 SD 0 (0)
 PD 10 (76.9)
 NE 2 (15.4)
ORR―% (95% CI) 7.7 (0.2–36.0)

Tumor response to c4G12 treatment was defined and recorded according to cRECIST v1.030.

CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR objective response rate (CR + PR), CI confidence interval.